{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T12:48:24Z","timestamp":1782391704533,"version":"3.54.5"},"reference-count":139,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"am","delay-in-days":349,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA039143-A1"],"award-info":[{"award-number":["R01DA039143-A1"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["OIA-1946391"],"award-info":[{"award-number":["OIA-1946391"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008519","name":"University of Arkansas for Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008519","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience &amp; Biobehavioral Reviews"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.neubiorev.2025.106043","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T02:42:32Z","timestamp":1738809752000},"page":"106043","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["The resurgence of synthetic cannabinoid receptor agonists as adulterants in the Era of Cannabis legalization: Lessons from prior epidemics and clinical implications"],"prefix":"10.1016","volume":"170","author":[{"given":"Austin T.","family":"Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa","family":"Marwan Abu Taha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4743-8187","authenticated-orcid":false,"given":"Grover P.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neubiorev.2025.106043_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.forsciint.2023.111613","article-title":"The identification of synthetic cannabinoids in English prisons","volume":"348","author":"Abbott","year":"2023","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.neubiorev.2025.106043_bib2","unstructured":"Agriculture Improvement Act of 2018, 2018."},{"key":"10.1016\/j.neubiorev.2025.106043_bib3","unstructured":"AKI associated with synthetic cannabinoids: a case series - PubMed [WWW Document], n.d. URL https:\/\/pubmed.ncbi.nlm.nih.gov\/23243266\/ (Accessed 11.1.23)."},{"key":"10.1016\/j.neubiorev.2025.106043_bib4","doi-asserted-by":"crossref","first-page":"93","DOI":"10.9740\/mhc.2019.03.093","article-title":"Review of the many faces of synthetic cannabinoid toxicities","volume":"9","author":"Alipour","year":"2019","journal-title":"Ment. Health Clin."},{"key":"10.1016\/j.neubiorev.2025.106043_bib5","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1176\/appi.ps.202100660","article-title":"Guidance for handling the increasing prevalence of drugs adulterated or laced with fentanyl","volume":"74","author":"Allen","year":"2023","journal-title":"Psychiatr. Serv. Wash. DC"},{"key":"10.1016\/j.neubiorev.2025.106043_bib6","first-page":"703","article-title":"Photochemical fingerprinting is a sensitive probe for the detection of synthetic cannabinoid receptor agonists; toward robust point-of-care detection","volume":"95","author":"Andrews","year":"2023","journal-title":"Anal. Chem."},{"key":"10.1016\/j.neubiorev.2025.106043_bib7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.forsciint.2018.09.008","article-title":"A review on the abuse of three NPS (synthetic cannabinoids, kratom, poppers) among youths in Asia","volume":"292","author":"Bae","year":"2018","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.neubiorev.2025.106043_bib8","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1124\/dmd.120.000073","article-title":"Predicting the potential for cannabinoids to precipitate pharmacokinetic drug interactions via reversible inhibition or inactivation of major cytochromes P450","volume":"48","author":"Bansal","year":"2020","journal-title":"Drug Metab. Dispos. Biol. Fate Chem."},{"key":"10.1016\/j.neubiorev.2025.106043_bib9","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1177\/0269881116658990","article-title":"Psychiatric comorbidity associated with synthetic cannabinoid use compared to cannabis","volume":"30","author":"Bassir Nia","year":"2016","journal-title":"J. Psychopharmacol. Oxf. Engl."},{"key":"10.1016\/j.neubiorev.2025.106043_bib10","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMp1404846","article-title":"Rethinking the social history","volume":"371","author":"Behforouz","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neubiorev.2025.106043_bib11","doi-asserted-by":"crossref","first-page":"523","DOI":"10.2215\/CJN.05690612","article-title":"AKI Associated with synthetic cannabinoids: a case series","volume":"8","author":"Bhanushali","year":"2013","journal-title":"Clin. J. Am. Soc. Nephrol. CJASN"},{"key":"10.1016\/j.neubiorev.2025.106043_bib12","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1098\/rspb.1983.0093","article-title":"Operational models of pharmacological agonism","volume":"220","author":"Black","year":"1983","journal-title":"Proc. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.neubiorev.2025.106043_bib13","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.drugpo.2016.10.015","article-title":"From niche to stigma\u2014Headshops to prison: exploring the rise and fall of synthetic cannabinoid use among young adults","volume":"40","author":"Blackman","year":"2017","journal-title":"Int. J. Drug Policy N. Psychoact. Subst. Hum. Enhanc. Drugs"},{"key":"10.1016\/j.neubiorev.2025.106043_bib14","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/npp.2017.209","article-title":"Clinical and preclinical evidence for functional interactions of cannabidiol and \u03949-tetrahydrocannabinol","volume":"43","author":"Boggs","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neubiorev.2025.106043_bib15","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/15504263.2014.989653","article-title":"PTSD and substance use disorder among veterans: characteristics, service utilization and pharmacotherapy","volume":"11","author":"Bowe","year":"2015","journal-title":"J. Dual Diagn."},{"key":"10.1016\/j.neubiorev.2025.106043_bib16","doi-asserted-by":"crossref","DOI":"10.1007\/s11606-024-08642-9","article-title":"Rethinking substance use as social history: charting a way forward","author":"Bozinoff","year":"2024","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.neubiorev.2025.106043_bib17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s42238-023-00176-x","article-title":"Unintentional ingestion of putative delta-8 tetrahydrocannabinol by two youth requiring critical care: a case report","volume":"5","author":"Bradley","year":"2023","journal-title":"J. Cannabis Res."},{"key":"10.1016\/j.neubiorev.2025.106043_bib18","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1124\/jpet.113.206003","article-title":"Differential Drug\u2013Drug Interactions of the Synthetic Cannabinoids JWH-018 and JWH-073: Implications for Drug Abuse Liability and Pain Therapy","volume":"346","author":"Brents","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.neubiorev.2025.106043_bib19","first-page":"S37","article-title":"Natural and synthetic cannabinoids: pharmacology, uses, adverse drug events, and drug interactions","volume":"61","author":"Brown","year":"2021","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.neubiorev.2025.106043_bib20","unstructured":"California D. (2023), Medicinal and Adult Use Commercial Cannabis Regulations."},{"key":"10.1016\/j.neubiorev.2025.106043_bib21","doi-asserted-by":"crossref","first-page":"9527","DOI":"10.1021\/acs.analchem.7b02552","article-title":"Activity-based detection of consumption of synthetic cannabinoids in authentic urine samples using a stable cannabinoid reporter system","volume":"89","author":"Cannaert","year":"2017","journal-title":"Anal. Chem."},{"key":"10.1016\/j.neubiorev.2025.106043_bib22","doi-asserted-by":"crossref","first-page":"11476","DOI":"10.1021\/acs.analchem.6b02600","article-title":"Detection and activity profiling of synthetic cannabinoids and their metabolites with a newly developed bioassay","volume":"88","author":"Cannaert","year":"2016","journal-title":"Anal. Chem."},{"key":"10.1016\/j.neubiorev.2025.106043_bib23","doi-asserted-by":"crossref","first-page":"16","DOI":"10.5409\/wjcp.v5.i1.16","article-title":"Synthetic cannabinoids 2015: an update for pediatricians in clinical practice","volume":"5","author":"Castellanos","year":"2016","journal-title":"World J. Clin. Pediatr."},{"key":"10.1016\/j.neubiorev.2025.106043_bib24","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/01.pra.0000413274.09305.9c","article-title":"Synthetic cannabinoid use: recognition and management","volume":"18","author":"Castellanos","year":"2012","journal-title":"J. Psychiatr. Pract."},{"key":"10.1016\/j.neubiorev.2025.106043_bib25","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1080\/08897077.2014.959151","article-title":"Synthetic cannabinoids: use and predictors in a community sample of young adults","volume":"36","author":"Caviness","year":"2015","journal-title":"Subst. Abus."},{"key":"10.1016\/j.neubiorev.2025.106043_bib26","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0145-2134(95)00144-1","article-title":"Onset of physical abuse and neglect: psychiatric, substance abuse, and social risk factors from prospective community data","volume":"20","author":"Chaffin","year":"1996","journal-title":"Child Abus. Negl."},{"key":"10.1016\/j.neubiorev.2025.106043_bib27","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1002\/1097-0142(19810401)47:7<1746::AID-CNCR2820470704>3.0.CO;2-4","article-title":"A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy","volume":"47","author":"Chang","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.neubiorev.2025.106043_bib28","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1124\/dmd.112.047530","article-title":"Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2\/Spice: identification of novel cannabinoid receptor ligands","volume":"40","author":"Chimalakonda","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.neubiorev.2025.106043_bib29","unstructured":"christiana, 2023. DEA Concludes Delta-8 and Delta-9 THC-O are Controlled Substances. Cent. US Policy. URL https:\/\/centerforuspolicy.org\/dea-concludes-delta-8-and-delta-9-thc-o-are-controlled-substances\/ (Accessed 3.10.24)."},{"key":"10.1016\/j.neubiorev.2025.106043_bib30","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jpeds.2015.06.001","article-title":"Myocardial ischemia secondary to synthetic cannabinoid (K2) use in pediatric patients","volume":"167","author":"Clark","year":"2015","journal-title":"J. Pediatr."},{"key":"10.1016\/j.neubiorev.2025.106043_bib31","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3389\/fpubh.2018.00162","article-title":"Synthetic and non-synthetic cannabinoid drugs and their adverse effects-a review from public health prospective","volume":"6","author":"Cohen","year":"2018","journal-title":"Front. Public Health"},{"key":"10.1016\/j.neubiorev.2025.106043_bib32","unstructured":"Common Comorbidities with Substance Use Disorders Research Report, 2020. National Institutes on Drug Abuse (US), Bethesda (MD)."},{"key":"10.1016\/j.neubiorev.2025.106043_bib33","unstructured":"Costas Insua, C., 2022. Searching for new cannabinoid CB1 receptor-interacting proteins."},{"key":"10.1016\/j.neubiorev.2025.106043_bib34","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.pharmthera.2019.05.001","article-title":"A marijuana-drug interaction primer: precipitants, pharmacology, and pharmacokinetics","volume":"201","author":"Cox","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neubiorev.2025.106043_bib35","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1111\/1556-4029.15304","article-title":"The effects of the (fentanyl-fueled) drug overdose epidemic on medicolegal death investigation in the United States","volume":"68","author":"Davis","year":"2023","journal-title":"J. Forensic Sci."},{"key":"10.1016\/j.neubiorev.2025.106043_bib36","unstructured":"Delphin-Rittmon, M.E., n.d. 2022 National Survey on Drug Use and Health: Among the Veteran Population Aged 12 or Older."},{"key":"10.1016\/j.neubiorev.2025.106043_bib37","doi-asserted-by":"crossref","first-page":"14619","DOI":"10.3390\/ijms232314619","article-title":"Molecular insights and clinical outcomes of drugs of abuse adulteration: new trends and new psychoactive substances","volume":"23","author":"Di Trana","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neubiorev.2025.106043_bib38","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1208\/s12248-021-00616-7","article-title":"Cannabinoid interactions with cytochrome P450 drug metabolism: a full-spectrum characterization","volume":"23","author":"Doohan","year":"2021","journal-title":"AAPS J."},{"key":"10.1016\/j.neubiorev.2025.106043_bib39","unstructured":"Drwes, 2010. Dr. Wes: Inhaled Incense \u201cK2\u201d May Cause Heart Damage. Dr Wes. URL https:\/\/drwes.blogspot.com\/2010\/08\/inhaled-incense-k2-may-cause-heart.html? (Accessed 3.10.24)."},{"key":"10.1016\/j.neubiorev.2025.106043_bib40","doi-asserted-by":"crossref","unstructured":"Edinoff, A.N., Swinford, C.R., Odisho, A.S., Burroughs, C.R., Stark, C.W., Raslan, W.A., Cornett, E.M., Kaye, A.M., Kaye, A.D., n.d. Clinically Relevant Drug Interactions with Monoamine Oxidase Inhibitors. Health Psychol. Res. 10, 39576. https:\/\/doi.org\/10.52965\/001c.39576.","DOI":"10.52965\/001c.39576"},{"key":"10.1016\/j.neubiorev.2025.106043_bib41","first-page":"1","article-title":"Phytochemistry of Cannabis sativa L","author":"ElSohly","year":"2017","journal-title":"Prog. Chem. Org. Nat. Prod."},{"key":"10.1016\/j.neubiorev.2025.106043_bib42","first-page":"361","article-title":"Synthetic cannabinoid bonzai related creatine kinase enzyme elevation: a Turkish center study","volume":"60","author":"Erismis","year":"2021","journal-title":"Acta Clin. Croat."},{"key":"10.1016\/j.neubiorev.2025.106043_bib43","first-page":"121","article-title":"Heroin adulterated with the novel synthetic cannabinoid, 5F-MDMB-PINACA: a case series","volume":"4","author":"Ershad","year":"2020","journal-title":"Clin. Pract. Cases Emerg. Med."},{"key":"10.1016\/j.neubiorev.2025.106043_bib44","unstructured":"European Monitoring Centre for Drugs and Drug Addiction, 2023. European drug report 2023, European drug report \u2026 (Online). Publications Office, LU."},{"key":"10.1016\/j.neubiorev.2025.106043_bib45","series-title":"EMCDDA\u2013Europol 2009 annual report on the implementation of Council Decision 2005\/387\/JHA","author":"European Monitoring Centre for Drugs and Drug Addiction & Europol","year":"2009"},{"key":"10.1016\/j.neubiorev.2025.106043_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fnbeh.2011.00060","article-title":"Beyond THC: the new generation of cannabinoid designer drugs","volume":"5","author":"Fattore","year":"2011","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.neubiorev.2025.106043_bib47","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1124\/jpet.117.246983","article-title":"Molecular and behavioral pharmacological characterization of abused synthetic cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-Fluoro-CUMYL-PICA","volume":"365","author":"Gamage","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neubiorev.2025.106043_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.mex.2023.102173","article-title":"Determination of synthetic cannabinoids in oral fluids by liquid chromatography with fluorescence detection after solid-phase extraction","volume":"10","author":"Garc\u00eda-Atienza","year":"2023","journal-title":"MethodsX"},{"key":"10.1016\/j.neubiorev.2025.106043_bib49","unstructured":"Goh, B.Y.H., 2023. Assessing First Responders and People Who Use Drugs\u2019 Perceptions of Fentanyl and Drug Checking Services (Thesis)."},{"key":"10.1016\/j.neubiorev.2025.106043_bib50","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1080\/15563650.2021.1994144","article-title":"Involuntary MDMB-4en-PINACA intoxications following cannabis consumption: clinical and analytical findings","volume":"60","author":"Goncalves","year":"2022","journal-title":"Clin. Toxicol. Phila. Pa"},{"key":"10.1016\/j.neubiorev.2025.106043_bib51","doi-asserted-by":"crossref","first-page":"509","DOI":"10.15288\/jsad.2016.77.509","article-title":"Associations of posttraumatic stress disorder symptoms with marijuana and synthetic cannabis use among young adult U.S. veterans: a pilot investigation","volume":"77","author":"Grant","year":"2016","journal-title":"J. Stud. Alcohol Drugs"},{"key":"10.1016\/j.neubiorev.2025.106043_bib52","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/02791072.2013.873843","article-title":"PTSD symptom reports of patients evaluated for the New Mexico Medical Cannabis Program","volume":"46","author":"Greer","year":"2014","journal-title":"J. Psychoact. Drugs"},{"key":"10.1016\/j.neubiorev.2025.106043_bib53","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1521-0391.2012.00240.x","article-title":"Spice\u201d and \u201cK2\u201d Herbal Highs: A Case Series and Systematic Review of the Clinical Effects and Biopsychosocial Implications of Synthetic Cannabinoid Use in Humans","volume":"21","author":"Gunderson","year":"2012","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.neubiorev.2025.106043_bib54","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1080\/08897077.2013.846288","article-title":"A survey of synthetic cannabinoid consumption by current cannabis users","volume":"35","author":"Gunderson","year":"2014","journal-title":"Subst. Abus."},{"key":"10.1016\/j.neubiorev.2025.106043_bib55","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.apsb.2016.07.016","article-title":"Insights into CYP2B6-mediated drug\u2013drug interactions","volume":"6","author":"Hedrich","year":"2016","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.neubiorev.2025.106043_bib56","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1360-0443.2012.04078.x","article-title":"Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings","volume":"108","author":"Hermanns-Clausen","year":"2013","journal-title":"Addict. Abingdon Engl."},{"key":"10.1016\/j.neubiorev.2025.106043_bib57","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0090-6980(00)00051-4","article-title":"Biochemistry and pharmacology of the endocannabinoids arachidonylethanolamide and 2-arachidonylglycerol","volume":"61","author":"Hillard","year":"2000","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.neubiorev.2025.106043_bib58","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1111\/febs.16741","article-title":"Synthetic cannabinoid receptor agonists are monoamine oxidase-a selective inhibitors","volume":"290","author":"Hindson","year":"2023","journal-title":"Febs J."},{"key":"10.1016\/j.neubiorev.2025.106043_bib59","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1208\/s12248-015-9788-7","article-title":"CYP3A4 mediates oxidative metabolism of the synthetic cannabinoid AKB-48","volume":"17","author":"Holm","year":"2015","journal-title":"AAPS J."},{"key":"10.1016\/j.neubiorev.2025.106043_bib60","doi-asserted-by":"crossref","unstructured":"Howlett, A.C., Abood, M.E., 2017. Chapter Five - CB1 and CB2 Receptor Pharmacology, in: Kendall, D., Alexander, S.P.H. (Eds.), Advances in Pharmacology, Cannabinoid Pharmacology. Academic Press, pp. 169\u2013206. https:\/\/doi.org\/10.1016\/bs.apha.2017.03.007.","DOI":"10.1016\/bs.apha.2017.03.007"},{"key":"10.1016\/j.neubiorev.2025.106043_bib61","doi-asserted-by":"crossref","first-page":"6190","DOI":"10.3390\/molecules26206190","article-title":"The spicy story of cannabimimetic indoles","volume":"26","author":"Howlett","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.neubiorev.2025.106043_bib62","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/jat\/bkz092","article-title":"Case report: synthetic cannabinoid deaths in state of florida prisoners","volume":"44","author":"Hvozdovich","year":"2020","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.neubiorev.2025.106043_bib63","unstructured":"Intoxication from Synthetic-Cannabinoid-Receptor Agonists Often Missed [WWW Document], n.d. ACEP Now. URL https:\/\/www.acepnow.com\/article\/intoxication-from-synthetic-cannabinoid-receptor-agonists-often-missed\/ (Accessed 3.10.24)."},{"key":"10.1016\/j.neubiorev.2025.106043_bib64","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.annemergmed.2022.03.004","article-title":"Acute opioid withdrawal following intramuscular administration of naloxone 1.6 mg: a prospective out-of-hospital series","volume":"80","author":"Isoardi","year":"2022","journal-title":"Ann. Emerg. Med."},{"key":"10.1016\/j.neubiorev.2025.106043_bib65","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jchromb.2018.05.049","article-title":"Implementation of a generic SFC-MS method for the quality control of potentially counterfeited medicinal cannabis with synthetic cannabinoids","volume":"1092","author":"Jambo","year":"2018","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life. Sci."},{"key":"10.1016\/j.neubiorev.2025.106043_bib66","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2133\/dmpk.DMPK-12-RG-129","article-title":"Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19","volume":"28","author":"Jiang","year":"2013","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.neubiorev.2025.106043_bib67","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.lfs.2011.05.018","article-title":"Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes","volume":"89","author":"Jiang","year":"2011","journal-title":"Life Sci."},{"key":"10.1016\/j.neubiorev.2025.106043_bib68","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s42238-023-00197-6","article-title":"Potency and safety analysis of hemp delta-9 products: the hemp vs. cannabis demarcation problem","volume":"5","author":"Johnson","year":"2023","journal-title":"J. Cannabis Res."},{"key":"10.1016\/j.neubiorev.2025.106043_bib69","unstructured":"K2\/Spice - Drug Fact Sheet [WWW Document], n.d. URL https:\/\/www.dea.gov\/documents\/2020\/2020-06\/2020-06-05\/k2spice-drug-fact-sheet (Accessed 11.1.23)."},{"key":"10.1016\/j.neubiorev.2025.106043_bib70","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s13181-023-00974-y","article-title":"Commercial delta-8 THC products: an analysis of content and labeling","volume":"20","author":"Kaczor","year":"2024","journal-title":"J. Med. Toxicol."},{"key":"10.1016\/j.neubiorev.2025.106043_bib71","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.1048836","article-title":"Off-target pharmacological profiling of synthetic cannabinoid receptor agonists including AMB-FUBINACA, CUMYL-PINACA, PB-22, and XLR-11","volume":"13","author":"Kevin","year":"2022","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.neubiorev.2025.106043_bib72","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/epirev\/mxx018","article-title":"Understanding and improving the health of people who experience incarceration: an overview and synthesis","volume":"40","author":"Kinner","year":"2018","journal-title":"Epidemiol. Rev."},{"key":"10.1016\/j.neubiorev.2025.106043_bib73","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1080\/15563650.2022.2099887","article-title":"Synthetic cannabinoid poisonings and access to the legal cannabis market: findings from US national poison centre data 2016-2019","volume":"60","author":"Klein","year":"2022","journal-title":"Clin. Toxicol. Phila. Pa"},{"key":"10.1016\/j.neubiorev.2025.106043_bib74","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/bcp.12071","article-title":"Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits \u03949-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans","volume":"76","author":"Klumpers","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.neubiorev.2025.106043_bib75","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/dta.2935","article-title":"The next generation of synthetic cannabinoids: detection, activity, and potential toxicity of pent-4en and but-3en analogues including MDMB-4en-PINACA","volume":"13","author":"Krotulski","year":"2021","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.neubiorev.2025.106043_bib76","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/jat\/bkz084","article-title":"Emerging synthetic cannabinoids: development and validation of a novel liquid chromatography quadrupole time-of-flight mass spectrometry assay for real-time detection","volume":"44","author":"Krotulski","year":"2020","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.neubiorev.2025.106043_bib77","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.51951","article-title":"Identification and health risks of an emerging means of drug use in correctional facilities","volume":"7","author":"Kuai","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.neubiorev.2025.106043_bib78","doi-asserted-by":"crossref","first-page":"5413","DOI":"10.3390\/molecules26175413","article-title":"CB1 cannabinoid receptor signaling and biased signaling","volume":"26","author":"Leo","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.neubiorev.2025.106043_bib79","doi-asserted-by":"crossref","unstructured":"Li, L., Chmura, S.E., Judd, C.D., Duffy, B.C., 2023. Chapter 7 - New York perspectives of medical cannabis laboratory analysis, in: Preedy, V.R., Patel, V.B., Martin, C.R. (Eds.), Medicinal Usage of Cannabis and Cannabinoids. Academic Press, pp. 77\u201389. https:\/\/doi.org\/10.1016\/B978-0-323-90036-2.00017-X.","DOI":"10.1016\/B978-0-323-90036-2.00017-X"},{"key":"10.1016\/j.neubiorev.2025.106043_bib80","first-page":"607","article-title":"Review of the endocannabinoid system","volume":"6","author":"Lu","year":"2021","journal-title":"Biol. Psychiatry Cogn. Neurosci. Neuroimaging"},{"key":"10.1016\/j.neubiorev.2025.106043_bib81","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.pbb.2014.05.010","article-title":"In vivo effects of synthetic cannabinoids JWH-018 and JWH-073 and phytocannabinoid \u03949-THC in mice: inhalation versus intraperitoneal injection","volume":"124","author":"Marshell","year":"2014","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neubiorev.2025.106043_bib82","article-title":"Synthetic cannabinoids in prisons: content analysis of TikToks","volume":"2","author":"McMann","year":"2022","journal-title":"JMIR Info"},{"key":"10.1016\/j.neubiorev.2025.106043_bib83","doi-asserted-by":"crossref","first-page":"e1622","DOI":"10.1542\/peds.2010-3823","article-title":"Myocardial infarction associated with use of the synthetic cannabinoid K2","volume":"128","author":"Mir","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.neubiorev.2025.106043_bib84","doi-asserted-by":"crossref","first-page":"204","DOI":"10.31389\/jied.122","article-title":"Potency-enhancing synthetics in the drug overdose epidemic: Xylazine (\u201cTranq\u201d), Fentanyl, Methamphetamine, and the displacement of heroin in philadelphia and Tijuana","volume":"4","author":"Montero","year":"2022","journal-title":"J. Illicit Econ. Dev."},{"key":"10.1016\/j.neubiorev.2025.106043_bib85","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1002\/dta.3220","article-title":"Adulteration of low-delta-9-tetrahydrocannabinol products with synthetic cannabinoids: results from drug checking services","volume":"14","author":"Monti","year":"2022","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.neubiorev.2025.106043_bib86","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1192\/bjp.bp.107.046649","article-title":"Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis","volume":"192","author":"Morgan","year":"2008","journal-title":"Br. J. Psychiatry J. Ment. Sci."},{"key":"10.1016\/j.neubiorev.2025.106043_bib87","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s11419-015-0270-0","article-title":"Comprehensive review of the detection methods for synthetic cannabinoids and cathinones","volume":"33","author":"Namera","year":"2015","journal-title":"Forensic Toxicol."},{"key":"10.1016\/j.neubiorev.2025.106043_bib88","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1124\/dmd.121.000442","article-title":"Cannabinoid metabolites as inhibitors of major hepatic CYP450 enzymes, with implications for cannabis-drug interactions","volume":"49","author":"Nasrin","year":"2021","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.neubiorev.2025.106043_bib89","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/dta.1860","article-title":"Cytochrome P450-mediated metabolism of the synthetic cannabinoids UR-144 and XLR-11","volume":"8","author":"Nielsen","year":"2016","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.neubiorev.2025.106043_bib90","doi-asserted-by":"crossref","first-page":"990","DOI":"10.3390\/brainsci13070990","article-title":"Toxicity of synthetic cannabinoids in K2\/Spice: a systematic review","volume":"13","author":"de Oliveira","year":"2023","journal-title":"Brain Sci."},{"key":"10.1016\/j.neubiorev.2025.106043_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2021.103493","article-title":"Cannabis adulterated with the synthetic cannabinoid receptor agonist MDMB-4en-PINACA and the role of European drug checking services","volume":"100","author":"Oomen","year":"2022","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.neubiorev.2025.106043_bib92","doi-asserted-by":"crossref","first-page":"S163","DOI":"10.1038\/sj.bjp.0706406","article-title":"Cannabinoid pharmacology: the first 66 years","volume":"147","author":"Pertwee","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neubiorev.2025.106043_bib93","unstructured":"E., Pirona, A., Surmont, T., Vandam, L., Borle, P., Mounteney, J., Gallegos, A., Singleton, N., Montanari, L., Griffiths, P., Hedrich, D., 2018. New psychoactive substances in prison: results from an EMCDDA trendspotter study. Publications Office of the European Union."},{"key":"10.1016\/j.neubiorev.2025.106043_bib94","doi-asserted-by":"crossref","first-page":"3790","DOI":"10.1111\/bph.13973","article-title":"Antidote to cannabinoid intoxication: the CB1 receptor inverse agonist, AM251, reverses hypothermic effects of the CB1 receptor agonist, CB-13, in mice","volume":"174","author":"Pryce","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neubiorev.2025.106043_bib95","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1017\/S1092852923002109","article-title":"Practical pharmacotherapy for opioid use disorder in the age of fentanyl","volume":"28","author":"Pyo","year":"2023","journal-title":"CNS Spectr."},{"key":"10.1016\/j.neubiorev.2025.106043_bib96","first-page":"123","article-title":"Mechanisms and the clinical relevance of complex drug\u2013drug interactions","volume":"10","author":"Roberts","year":"2018","journal-title":"Clin. Pharmacol. Adv. Appl."},{"key":"10.1016\/j.neubiorev.2025.106043_bib97","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s11419-021-00586-7","article-title":"Synthetic cannabinoid receptor agonists profile in infused papers seized in Brazilian prisons","volume":"40","author":"Rodrigues","year":"2022","journal-title":"Forensic Toxicol."},{"key":"10.1016\/j.neubiorev.2025.106043_bib98","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/CRD.0b013e3181c307b7","article-title":"Hypertensive crisis","volume":"18","author":"Rodriguez","year":"2010","journal-title":"Cardiol. Rev."},{"key":"10.1016\/j.neubiorev.2025.106043_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2022.103756","article-title":"Does cannabis testing in the military drive synthetic cannabinoid use? Self-reported use motivations among justice-involved veterans","volume":"106","author":"Santangelo","year":"2022","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.neubiorev.2025.106043_bib100","first-page":"85","article-title":"Synthetic cannabinoid analogues--not repeating past mistakes","volume":"124","author":"Schep","year":"2011","journal-title":"N. Z. Med. J."},{"key":"10.1016\/j.neubiorev.2025.106043_bib101","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2022.1044575","article-title":"Cys-loop receptors on cannabinoids: all high?","volume":"13","author":"Schmiedhofer","year":"2022","journal-title":"Front. Physiol."},{"key":"10.1016\/j.neubiorev.2025.106043_bib102","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1360-0443.2006.01592.x","article-title":"Comorbidity between substance use disorders and psychiatric conditions","volume":"101","author":"Schuckit","year":"2006","journal-title":"Addiction"},{"key":"10.1016\/j.neubiorev.2025.106043_bib103","series-title":"Encyclopedia of Forensic and Legal Medicine","first-page":"394","article-title":"Substance Misuse: Legal Highs","author":"Scott-Ham","year":"2016"},{"key":"10.1016\/j.neubiorev.2025.106043_bib104","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1001\/archinte.167.5.476","article-title":"Bringing the war back home: mental health disorders among 103,788 US veterans returning from Iraq and Afghanistan seen at Department of Veterans Affairs facilities","volume":"167","author":"Seal","year":"2007","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.neubiorev.2025.106043_bib105","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.drugalcdep.2010.11.027","article-title":"Substance use disorders in Iraq and Afghanistan veterans in VA healthcare, 2001-2010: implications for screening, diagnosis and treatment","volume":"116","author":"Seal","year":"2011","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neubiorev.2025.106043_bib106","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/pst.426","article-title":"Guidelines for accurate EC50\/IC50 estimation","volume":"10","author":"Sebaugh","year":"2011","journal-title":"Pharm. Stat."},{"key":"10.1016\/j.neubiorev.2025.106043_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2021.462743","article-title":"Simultaneous screening of 239 synthetic cannabinoids and metabolites in blood and urine samples using liquid chromatography-high resolution mass spectrometry","volume":"1663","author":"Shi","year":"2022","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.neubiorev.2025.106043_bib108","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2020.173059","article-title":"Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids","volume":"199","author":"Sholler","year":"2020","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neubiorev.2025.106043_bib109","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1177\/0033354919887741","article-title":"The emerging role of toxic adulterants in street drugs in the US illicit opioid crisis","volume":"135","author":"Singh","year":"2019","journal-title":"Public Health Rep."},{"key":"10.1016\/j.neubiorev.2025.106043_bib110","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00702-019-02132-7","article-title":"Cannabinoid1 (CB-1) receptor antagonists: a molecular approach to treating acute cannabinoid overdose","volume":"127","author":"Skolnick","year":"2020","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.neubiorev.2025.106043_bib111","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1056\/NEJMp1106985","article-title":"Complicated lives \u2014 taking the social history","volume":"365","author":"Srivastava","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neubiorev.2025.106043_bib112","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/ajad.13482","article-title":"Brief report: synthetic cannabinoid use among military personnel","volume":"33","author":"Stogner","year":"2024","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.neubiorev.2025.106043_bib113","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3109\/03602532.2013.849268","article-title":"Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review","volume":"46","author":"Stout","year":"2014","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.neubiorev.2025.106043_bib114","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1093\/clinchem\/hvac045","article-title":"Towards a new qualitative screening assay for synthetic cannabinoids using metabolomics and machine learning","volume":"68","author":"Streun","year":"2022","journal-title":"Clin. Chem."},{"key":"10.1016\/j.neubiorev.2025.106043_bib115","unstructured":"Substance Abuse and Mental Health Data Archive [WWW Document], n.d. URL https:\/\/www.samhsa.gov\/data\/data-we-collect\/samhda-substance-abuse-and-mental-health-data-archive (Accessed 3.10.24)."},{"key":"10.1016\/j.neubiorev.2025.106043_bib116","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s40429-014-0014-y","article-title":"Synthetic cannabinoids: pharmacology, behavioral effects, and abuse potential","volume":"1","author":"Tai","year":"2014","journal-title":"Curr. Addict. Rep."},{"key":"10.1016\/j.neubiorev.2025.106043_bib117","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12245-021-00330-3","article-title":"The emergency department care of the cannabis and synthetic cannabinoid patient: a narrative review","volume":"14","author":"Takakuwa","year":"2021","journal-title":"Int. J. Emerg. Med."},{"key":"10.1016\/j.neubiorev.2025.106043_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108311","article-title":"Prescription opioid misuse and its correlates among veterans and military in the United States: a systematic literature review","volume":"216","author":"Tam","year":"2020","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neubiorev.2025.106043_bib119","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1080\/15563650.2023.2177552","article-title":"Cannabis positivity rates in 17 emergency departments across the United States with varying degrees of marijuana legalization","volume":"61","author":"Tolan","year":"2023","journal-title":"Clin. Toxicol. Phila. Pa"},{"key":"10.1016\/j.neubiorev.2025.106043_bib120","unstructured":"Valliere, M., 2019. A Synthetic Biochemistry Platform for the Enzymatic Synthesis of Cannabinoids and Other Prenylated Natural Products. UCLA."},{"key":"10.1016\/j.neubiorev.2025.106043_bib121","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.drugalcdep.2011.07.011","article-title":"A survey study to characterize use of Spice products (synthetic cannabinoids)","volume":"120","author":"Vandrey","year":"2012","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neubiorev.2025.106043_bib122","article-title":"New York state Cannabis sativa L","author":"Vergara","year":"2023","journal-title":"Prod. Man."},{"key":"10.1016\/j.neubiorev.2025.106043_bib123","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.addbeh.2018.04.011","article-title":"Military status and alcohol problems: former soldiers may be at greater risk","volume":"84","author":"Vest","year":"2018","journal-title":"Addict. Behav."},{"key":"10.1016\/j.neubiorev.2025.106043_bib124","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.addbeh.2014.02.018","article-title":"Spicing up the military: use and effects of synthetic cannabis in substance abusing army personnel","volume":"39","author":"Walker","year":"2014","journal-title":"Addict. Behav."},{"key":"10.1016\/j.neubiorev.2025.106043_bib125","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1080\/19336950.2019.1615824","article-title":"Cannabinoid interactions with ion channels and receptors","volume":"13","author":"Watkins","year":"2019","journal-title":"Channels"},{"key":"10.1016\/j.neubiorev.2025.106043_bib126","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1081\/ADA-200037538","article-title":"Prevalence and characteristics of clients with co-occurring disorders in outpatient substance abuse treatment","volume":"30","author":"Watkins","year":"2004","journal-title":"Am. J. Drug Alcohol Abus."},{"key":"10.1016\/j.neubiorev.2025.106043_bib127","series-title":"Veterans Health Administration Mental Health Program Evaluation: Capstone Report","author":"Watkins","year":"2011"},{"key":"10.1016\/j.neubiorev.2025.106043_bib128","first-page":"13","article-title":"Fentanyl exposure and detection strategies utilized by clinical trial participants seeking linkage to opioid use disorder treatment at a syringe service program","volume":"20","author":"Watson","year":"2024","journal-title":"J. Med. Toxicol. Off. J. Am. Coll. Med. Toxicol."},{"key":"10.1016\/j.neubiorev.2025.106043_bib129","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1345\/aph.1P580","article-title":"The \u201cnew\u201d marijuana","volume":"45","author":"Wells","year":"2011","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.neubiorev.2025.106043_bib130","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/hup.2292","article-title":"The 12-month prevalence and nature of adverse experiences resulting in emergency medical presentations associated with the use of synthetic cannabinoid products","volume":"28","author":"Winstock","year":"2013","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.neubiorev.2025.106043_bib131","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.lfs.2011.02.017","article-title":"Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety","volume":"88","author":"Yamaori","year":"2011","journal-title":"Life Sci."},{"key":"10.1016\/j.neubiorev.2025.106043_bib132","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1345\/aph.1M064","article-title":"Probable interaction between warfarin and marijuana smoking","volume":"43","author":"Yamreudeewong","year":"2009","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.neubiorev.2025.106043_bib133","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/milmed\/usab485","article-title":"The public health approach to the worsening opioid crisis in the united states calls for harm reduction strategies to mitigate the harm from opioid addiction and overdose deaths","volume":"187","author":"Yeo","year":"2022","journal-title":"Mil. Med."},{"key":"10.1016\/j.neubiorev.2025.106043_bib134","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1039\/C6TX00259E","article-title":"Synthetic cannabinoid, JWH-030, induces QT prolongation through hERG channel inhibition","volume":"5","author":"Yun","year":"2016","journal-title":"Toxicol. Res."},{"key":"10.1016\/j.neubiorev.2025.106043_bib135","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neubiorev.2025.106043_bib136","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000536339","article-title":"Cannabidiol-derived cannabinoids: the unregulated designer drug market following the 2018 farm bill","volume":"7","author":"Zawatsky","year":"2024","journal-title":"Med. Cannabis Cannabinoids"},{"key":"10.1016\/j.neubiorev.2025.106043_bib137","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00213-011-2495-x","article-title":"Interaction between cannabidiol (CBD) and \u2206(9)-tetrahydrocannabinol (THC): influence of administration interval and dose ratio between the cannabinoids","volume":"219","author":"Zuardi","year":"2012","journal-title":"Psychopharmacol. (Berl. )"},{"key":"10.1016\/j.neubiorev.2025.106043_bib138","first-page":"12","article-title":"Pharmacological interaction of the effects of delta 9-trans-tetrahydrocannabinol and cannabidiol on serum corticosterone levels in rats","volume":"269","author":"Zuardi","year":"1984","journal-title":"Arch. Int. Pharmacodyn. Ther."},{"key":"10.1016\/j.neubiorev.2025.106043_bib139","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1177\/0269881108096509","article-title":"Inhibition of THC-induced effects on the central nervous system and heart rate by a novel CB1 receptor antagonist AVE1625","volume":"24","author":"Zuurman","year":"2010","journal-title":"J. Psychopharmacol. Oxf. Engl."}],"container-title":["Neuroscience &amp; Biobehavioral Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149763425000430?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149763425000430?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T09:09:00Z","timestamp":1762247340000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149763425000430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":139,"alternative-id":["S0149763425000430"],"URL":"https:\/\/doi.org\/10.1016\/j.neubiorev.2025.106043","relation":{},"ISSN":["0149-7634"],"issn-type":[{"value":"0149-7634","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The resurgence of synthetic cannabinoid receptor agonists as adulterants in the Era of Cannabis legalization: Lessons from prior epidemics and clinical implications","name":"articletitle","label":"Article Title"},{"value":"Neuroscience & Biobehavioral Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neubiorev.2025.106043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106043"}}